The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Two senators wrote to the FDA Friday about the Hims Super Bowl ad, which they said misleads patients about compounded weight ...

Listen to more stories on the Noa app. The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Hims & Hers Health (HIMS) stock hits an all-time high as the company's controversial Super Bowl ad is set to air this Sunday ...

Hims & Hers sells a compounded weight loss medication. A telehealth company that sells a compounded version of medications used for weight loss has found itself at the center of an escalating ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $60.30, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%.

Hims & Hers has capitalized on the outsize consumer demand for obesity drugs. (Hims & Hers Health) Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug ...

Hims & Hers Health, Inc. (HIMS) shares rallied 27.7% in the last trading session to close at $59.18. This move can be attributable to notable volume with a higher number of shares being traded ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...